W
WAVEMAN · COMPANY
ZLAB · Zai Lab Ltd
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

ZLAB

Zai Lab Ltd
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001704292
FORM 144 · 9☆ WATCH
INSIDER NET · 180D
-$7.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
44
13F, latest reported quarter
REVENUE GROWTH
+15.0%
XBRL, annual
NET MARGIN
-38.4%
CONVERSIONS · 180D
33
codes C/M, not in net · $1.3M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$7.1M over 180 days
-$999.3K over 90 days
below 81% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
44 funds added or opened last quarter
below 57% of Pharma & Biotech
REVENUE
+15.0% year over year
more than 65% of Pharma & Biotech
MARGIN
-38.4% net margin
below 55% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$7.1M across 6 people in 180 days.
44 funds added or opened positions in the latest 13F quarter, of 94 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -20.6%
-20.6%12M
-51%-33%-15%+3%2025-092025-102025-122026-032026-052026-072026-09 2026-05-15 · Du Ying sold $1.0M2026-05-14 · Du Ying sold $1.0M2026-03-06 · Du Ying sold $971.0K2026-03-05 · Du Ying sold $961.0K2026-03-09 · Du Ying sold $951.5K2026-05-18 · Du Ying sold $950.0K2026-03-04 · Du Ying sold $689.9K2026-05-13 · Du Ying sold $682.8K2026-06-26 · Du Ying sold $428.5K2026-05-13 · Du Ying sold $315.5K2026-03-05 · Edmondson Frazor Titus III sold $296.7K2025-09-10 · Smiley Joshua L bought $289.1K2025-11-21 · Edmondson Frazor Titus III sold $283.4K2026-03-04 · Du Ying sold $268.4K2026-08-12 · Lis William sold $212.7K2026-04-02 · Amado Rafael sold $202.1K2026-04-02 · Smiley Joshua L sold $196.0K2025-12-31 · Amado Rafael sold $188.0K2026-03-03 · Amado Rafael sold $173.8K2025-12-16 · Edmondson Frazor Titus III sold $148.3K2026-06-30 · Du Ying sold $130.2K2026-06-22 · Lis William sold $127.4K2026-04-02 · Du Ying sold $113.7K2026-04-02 · Chen Yajing sold $106.0K2026-04-02 · Edmondson Frazor Titus III sold $85.5K2026-06-26 · Edmondson Frazor Titus III sold $71.6K2026-05-14 · Edmondson Frazor Titus III sold $71.0K2026-04-06 · Smiley Joshua L sold $61.7K2026-04-06 · Amado Rafael sold $56.0K2026-03-13 · Amado Rafael sold $55.1K2026-04-06 · Du Ying sold $54.3K2026-06-26 · Chen Yajing sold $39.5K2026-03-13 · Smiley Joshua L sold $36.6K2026-07-01 · GAYNOR RICHARD bought $33.1K2026-03-17 · GAYNOR RICHARD bought $32.7K2026-03-13 · Chen Yajing sold $31.7K2026-04-06 · Edmondson Frazor Titus III sold $25.0K2026-03-13 · Edmondson Frazor Titus III sold $23.9K2026-03-11 · Du Ying sold $20.4K2026-04-06 · Chen Yajing sold $17.4K2025-10-02 · Chen Yajing sold $15.6K2026-08-11 · Chen Yajing sold $15.5K2026-08-20 · Smiley Joshua L filed to sell $2.6M2026-08-19 · Chen Yajing filed to sell $7.0K2026-08-12 · Lis William filed to sell $212.7K2026-08-11 · Chen Yajing filed to sell $15.5K2026-06-30 · Du Ying filed to sell $130.2K2026-06-26 · Chen Yajing filed to sell $39.5K2026-06-26 · Du Ying filed to sell $428.6K2026-06-26 · Edmondson Frazor Titus III filed to sell $71.6K2026-06-22 · Lis William filed to sell $127.4K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $7.1M sold by insiders over 180 days, 44 funds added last quarter, $3.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Zai Lab Ltd insiders sold a net $7.1M of stock across 241 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Chen Yajing
Chief Financial Officer
SELL
2026-08-19
260.0
$7.0K
Lis William
Director
SELL
2026-08-12
8,506.0
$212.7K
Chen Yajing
Chief Financial Officer
SELL
2026-08-11
619.0
$15.5K
GAYNOR RICHARD
Director
BUY
2026-07-01
1,736.0
$33.1K
Du Ying
Chairperson & CEO
SELL
2026-06-30
7,026.0
$130.2K
241 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 236 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RTW INVESTMENTS, LP
6,574,032.0 sh
$124.9M
TCG Crossover Management, LLC
6,137,627.0 sh
$116.6M
RA CAPITAL MANAGEMENT, L.P.
5,743,533.0 sh
$109.1M
ADAR1 Capital Management, LLC
3,369,034.0 sh
$64.0M
FMR LLC
2,815,214.0 sh
$53.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Smiley Joshua L
FILED 2026-08-20
$2.6M
Chen Yajing
FILED 2026-08-19
$7.0K
Lis William
FILED 2026-08-12
$212.7K
Chen Yajing
FILED 2026-08-11
$15.5K
Du Ying
FILED 2026-06-30
$130.2K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Etf
$1.2M POSITION · AS OF 2026-04-30
1.9%
Tema Oncology ETF
$2.3M POSITION · AS OF 2026-02-28
1.5%
ALPS Medical Breakthroughs ETF
$1.9M POSITION · AS OF 2026-02-28
1.4%
Fidelity Disruptive Medicine ETF
$469.7K POSITION · AS OF 2026-02-28
0.8%
Baron Emerging Markets Fund
$26.0M POSITION · AS OF 2026-03-31
0.8%
Baron International Growth Fund
$1.5M POSITION · AS OF 2026-03-31
0.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Samantha (Ying) Du
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$10.7M
$1.9M
$3.8M
-87%
+25%
2024
$9.1M
$12.1M
$3.6M
-81%
-7%
2023
$12.0M
$7.5M
$3.9M
-80%
-6%
2022
$20.2M
$739.6K
$6.8M
-77%
-10%
2021
$15.3M
-$30.5M
$6.2M
-54%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$457.2M$397.6M$266.7M$212.7M
OPERATING INCOME$-229.4M$-282.1M$-366.6M$-404.4M
NET INCOME$-175.5M$-257.1M$-334.6M$-443.3M
EPS (DILUTED)-0.16-0.26-0.35-0.46
OPERATING CASH FLOW$-150.8M$-214.9M$-198.2M$-367.6M
CASH$679.6M$449.7M$790.2M$1.0B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →